Biotech: Page
-
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.
By Jacob Bell • Nov. 3, 2026 -
News roundup
UniQure gets an FDA decision date; Teva scraps brain drug study
The FDA appears likely to hold an advisory committee for UniQure’s closely watched Huntington’s disease gene therapy. Elsewhere, a biotech’s share price was cut in half following a regulatory setback.
By BioPharma Dive staff • Nov. 3, 2026 -
Explore the Trendline➔
Spencer Platt via Getty Images
TrendlineEmerging biotech
New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.
By BioPharma Dive staff -
Karyopharm, deep in debt, to sell itself in bankruptcy
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which recently cut a forbearance deal to push off debt payments.
By Jonathan Gardner • Nov. 2, 2026 -
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
By Ben Fidler • Nov. 2, 2026 -
This week in charts
This week in charts: ESMO’s winners and losers
The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.
By Jonathan Gardner • Oct. 30, 2026 -
Startup launches
With Setara, the team behind Actio opens its second act
The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that Actio was working on when Jazz Pharmaeuticals bought its lead epilepsy program.
By Gwendolyn Wu • Oct. 30, 2026 -
IPO window
Aspen raises a $141M IPO in pursuit of a cell therapy for Parkinson’s
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or even halt the neurodegenerative condition.
By Gwendolyn Wu • Oct. 29, 2026 -
Startup launches
Flagship blends three biotech startups to form Etcelera
Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.
By Gwendolyn Wu • Oct. 29, 2026 -
News roundup
Lilly shuffles business structure; Novartis writes off part of Avidity deal
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
By BioPharma Dive staff • Oct. 28, 2026 -
Ferring to acquire next-gen IVF startup Gameto for up to $1.4B
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro fertilization.
By Delilah Alvarado • Updated Oct. 28, 2026 -
Immune reset
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.
By Gwendolyn Wu • Oct. 27, 2026 -
Obesity drugs
Corxel, an obesity drugmaker, to go public via SPAC deal
Armed with a $300 million financing and two GLP-1 and amylin-targeting medicines, Corxel is set to become the latest weight loss-focused company to join the public markets.
By Gwendolyn Wu • Oct. 26, 2026 -
News roundup
Another autoimmune CAR-T death; Treasury zeroes in on China deals
A patient who received Bristol Myers’ zola-cel died 44 days later. Elsewhere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
By Ben Fidler • Oct. 26, 2026 -
Sponsored by Cytiva
Novel protein and peptide therapeutics
Explore manufacturing challenges and solutions for ADCs, bispecifics, peptides and more.
Oct. 26, 2026 -
This week in charts
This week in charts: a big year for RNAi developers
The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.
By Delilah Alvarado • Oct. 23, 2026 -
Star adds $200M after spinout successes
Following exits for its subsidiaries Electra Therapeutics and Vega Therapeutics, Star is now mining for a new drug prospect.
By Gwendolyn Wu • Oct. 23, 2026 -
IPO window
Protein degrader specialist Lycia prices $318M IPO
Funds from the upsized offering will support a trio of protein-degrading medicines in development for allergic conditions as well as the autoimmune disorder Graves’ disease.
By Gwendolyn Wu • Oct. 22, 2026 -
Roivant, continuing ascent, claims another victory for rare disease drug
Shortly after winning a clearance in the skin disease dermatomyositis, brepocitinib posted results suggesting it might also be a “best-in-disease” medicine for an inflammatory eye condition, one analyst said.
By Kristin Jensen • Oct. 21, 2026 -
News roundup
Arcus kidney cancer data impresses analysts; TriGemX inks a SPAC deal
New follow-up results suggest Arcus’ drug might be superior to a marketed Merck medicine. Elsewhere, Eli Lilly and AstraZeneca forged new partnerships.
By Ben Fidler • Oct. 21, 2026 -
Rapport’s epilepsy drug finds surprising success in bipolar trial
Despite what some analysts described as low expectations, RAP-219 narrowly hit the main goal of a mid-stage study, results that could help it tap a billion-dollar-plus market opportunity.
By Jacob Bell • Oct. 20, 2026 -
Disc’s once-spurned rare disease drug to get a second chance at approval
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.
By Delilah Alvarado • Oct. 19, 2026 -
Merck KGaA bets on RNAi with $1.3B Silence buyout
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
By Jonathan Gardner • Oct. 19, 2026 -
King Saud bin Abdulaziz University for Health Sciences (KSAU-HS) / University Relations and Media Affairs
Sponsored by The Riyadh Global Medical Biotechnology SummitFrom strategy to scale: How Saudi Arabia is building a biotech ecosystem
Saudi Arabia’s biotech strategy now has named partners, sites and capital behind it.
Oct. 19, 2026 -
Q&A // IPO window
Iambic CEO on taking an AI drug company public
Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.
By Jacob Bell • Oct. 16, 2026 -
This week in charts
This week in charts: Moderna’s massive stock run
The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.
By Delilah Alvarado • Oct. 16, 2026